Aceso Life Science Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Aceso Life Science Group şirketinin toplam hissedar öz sermayesi HK$1.8B ve toplam borcu HK$2.7B olup, bu da borç-öz sermaye oranını 150% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla HK$4.8B ve HK$3.0B dir.

Anahtar bilgiler

150.0%

Borç/özkaynak oranı

HK$2.72b

Borç

Faiz karşılama oranı	n/a
Nakit	HK$469.00m
Eşitlik	HK$1.81b
Toplam yükümlülükler	HK$2.97b
Toplam varlıklar	HK$4.79b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Feb 23

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Jan 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 474 'nin kısa vadeli varlıkları ( HK$1.3B ) kısa vadeli yükümlülüklerini ( HK$2.2B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 474 şirketinin kısa vadeli varlıkları ( HK$1.3B ) uzun vadeli yükümlülüklerini ( HK$759.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 474 'nin net borç/öz sermaye oranı ( 124.1% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 474 şirketinin borç/öz sermaye oranı son 5 yılda 90.6% seviyesinden 150% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 474 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 474 serbest nakit akışı her yıl % 39 oranında tarihsel oranda büyümeye devam ederse 3 yıldan fazla bir süre için yeterli nakit akışına sahip olur

Aceso Life Science Group Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Aceso Life Science Group Limited to Report First Half, 2025 Results on Nov 28, 2024

New minor risk - Share price stability

Insufficient new directors

Full year 2024 earnings released: HK$0.064 loss per share (vs HK$0.036 loss in FY 2023)

Aceso Life Science Group Limited, Annual General Meeting, Sep 19, 2024

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

New major risk - Revenue size

Aceso Life Science Group Limited Provides Group Earnings Guidance for the Six Months Ended 30 September 2023

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

New minor risk - Market cap size

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

Aceso Life Science Group Limited Consolidated Earnings Guidance for the Six Months Ended 30 September 2022

Aceso Life Science Group Limited to Report First Half, 2023 Results on Nov 29, 2022

Aceso Life Science Group Limited (SEHK:474) agreed to acquire 4% stake in Quanzhou Donghai Bay Asset Management Company Limited for approximately CNY180 million.

Aceso Life Science Group Limited Announces Change of Company Secretary

Full year 2022 earnings released: HK$0.051 loss per share (vs HK$0.057 loss in FY 2021)

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Full year 2022 earnings released

Aceso Life Science Group Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Aceso Life Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Non-Executive Director Yao Li has left the company

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Senior Consultant recently sold HK$5.0m worth of stock

First half 2021 earnings released: HK$0.07 loss per share

New 90-day low: HK$0.23

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.07 loss per share

Aceso Life Science Group Limited to Report First Half, 2021 Results on Nov 25, 2020

New 90-day low: HK$0.28

Senior Consultant recently bought HK$852k worth of stock

Hao Tian Development Group Limited has completed a Follow-on Equity Offering in the amount of HKD 150 million.

Senior Consultant recently bought HK$2.8m worth of stock

New 90-day high - HK$0.34

Full year earnings released - HK$0.049 loss per share

Hao Tian Development Group Limited to Report Fiscal Year 2020 Results on Jun 29, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin